A systematic analysis of splicing variants identifies new diagnoses in the 100,000 Genomes Project.


Journal

Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844

Informations de publication

Date de publication:
26 07 2022
Historique:
received: 02 02 2022
accepted: 13 07 2022
entrez: 26 7 2022
pubmed: 27 7 2022
medline: 29 7 2022
Statut: epublish

Résumé

Genomic variants which disrupt splicing are a major cause of rare genetic diseases. However, variants which lie outside of the canonical splice sites are difficult to interpret clinically. Improving the clinical interpretation of non-canonical splicing variants offers a major opportunity to uplift diagnostic yields from whole genome sequencing data. Here, we examine the landscape of splicing variants in whole-genome sequencing data from 38,688 individuals in the 100,000 Genomes Project and assess the contribution of non-canonical splicing variants to rare genetic diseases. We use a variant-level constraint metric (the mutability-adjusted proportion of singletons) to identify constrained functional variant classes near exon-intron junctions and at putative splicing branchpoints. To identify new diagnoses for individuals with unsolved rare diseases in the 100,000 Genomes Project, we identified individuals with de novo single-nucleotide variants near exon-intron boundaries and at putative splicing branchpoints in known disease genes. We identified candidate diagnostic variants through manual phenotype matching and confirmed new molecular diagnoses through clinical variant interpretation and functional RNA studies. We show that near-splice positions and splicing branchpoints are highly constrained by purifying selection and harbour potentially damaging non-coding variants which are amenable to systematic analysis in sequencing data. From 258 de novo splicing variants in known rare disease genes, we identify 35 new likely diagnoses in probands with an unsolved rare disease. To date, we have confirmed a new diagnosis for six individuals, including four in whom RNA studies were performed. Overall, we demonstrate the clinical value of examining non-canonical splicing variants in individuals with unsolved rare diseases.

Sections du résumé

BACKGROUND
Genomic variants which disrupt splicing are a major cause of rare genetic diseases. However, variants which lie outside of the canonical splice sites are difficult to interpret clinically. Improving the clinical interpretation of non-canonical splicing variants offers a major opportunity to uplift diagnostic yields from whole genome sequencing data.
METHODS
Here, we examine the landscape of splicing variants in whole-genome sequencing data from 38,688 individuals in the 100,000 Genomes Project and assess the contribution of non-canonical splicing variants to rare genetic diseases. We use a variant-level constraint metric (the mutability-adjusted proportion of singletons) to identify constrained functional variant classes near exon-intron junctions and at putative splicing branchpoints. To identify new diagnoses for individuals with unsolved rare diseases in the 100,000 Genomes Project, we identified individuals with de novo single-nucleotide variants near exon-intron boundaries and at putative splicing branchpoints in known disease genes. We identified candidate diagnostic variants through manual phenotype matching and confirmed new molecular diagnoses through clinical variant interpretation and functional RNA studies.
RESULTS
We show that near-splice positions and splicing branchpoints are highly constrained by purifying selection and harbour potentially damaging non-coding variants which are amenable to systematic analysis in sequencing data. From 258 de novo splicing variants in known rare disease genes, we identify 35 new likely diagnoses in probands with an unsolved rare disease. To date, we have confirmed a new diagnosis for six individuals, including four in whom RNA studies were performed.
CONCLUSIONS
Overall, we demonstrate the clinical value of examining non-canonical splicing variants in individuals with unsolved rare diseases.

Identifiants

pubmed: 35883178
doi: 10.1186/s13073-022-01087-x
pii: 10.1186/s13073-022-01087-x
pmc: PMC9327385
doi:

Substances chimiques

RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

79

Subventions

Organisme : National Institute for Health Research
ID : RP-2016-07-011
Organisme : Wellcome Trust
ID : 220134/Z/20/Z
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

Bioinformatics. 2010 Sep 1;26(17):2204-7
pubmed: 20639541
Nat Genet. 2014 Sep;46(9):944-50
pubmed: 25086666
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Nat Commun. 2020 May 27;11(1):2523
pubmed: 32461616
Hum Mutat. 2018 Nov;39(11):1517-1524
pubmed: 30192042
Cell. 2019 Jan 24;176(3):535-548.e24
pubmed: 30661751
Genet Med. 2022 Feb;24(2):398-409
pubmed: 34906448
Genome Res. 2018 Jul;28(7):968-974
pubmed: 29858273
RNA. 2018 Dec;24(12):1647-1658
pubmed: 30224349
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Genome Res. 2010 Jan;20(1):110-21
pubmed: 19858363
Cells. 2019 Nov 26;8(12):
pubmed: 31779139
Int J Biochem Cell Biol. 2019 Mar;108:61-71
pubmed: 30594648
N Engl J Med. 2021 Nov 11;385(20):1868-1880
pubmed: 34758253
Nat Genet. 2014 Aug;46(8):912-918
pubmed: 25017105
Nat Commun. 2019 May 30;10(1):2373
pubmed: 31147538
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Nat Rev Genet. 2018 May;19(5):253-268
pubmed: 29398702
Gigascience. 2021 Feb 16;10(2):
pubmed: 33590861
Sci Transl Med. 2017 Apr 19;9(386):
pubmed: 28424332
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Nature. 2018 Mar 29;555(7698):611-616
pubmed: 29562236
Sci Rep. 2021 Oct 18;11(1):20607
pubmed: 34663891
Genome Res. 2019 Feb;29(2):159-170
pubmed: 30587507
Diabetes. 2008 Jun;57(6):1659-63
pubmed: 18268044
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Mol Biol Evol. 1996 Nov;13(9):1219-23
pubmed: 8896374
Commun Biol. 2021 Oct 21;4(1):1206
pubmed: 34675361
Science. 2015 May 8;348(6235):666-9
pubmed: 25954003
BMC Genomics. 2020 Jan 28;21(1):86
pubmed: 31992191
J Med Genet. 2022 May;59(5):438-444
pubmed: 33910932
Nucleic Acids Res. 2019 Jan 8;47(D1):D766-D773
pubmed: 30357393
Bioinformatics. 2018 Mar 15;34(6):920-927
pubmed: 29092009
Genet Med. 2021 Dec;23(12):2360-2368
pubmed: 34429528
Genome Med. 2020 Apr 24;12(1):36
pubmed: 32331533
Hum Genet. 2017 Sep;136(9):1093-1111
pubmed: 28497172

Auteurs

Alexander J M Blakes (AJM)

Faculty of Medicine, Human Development and Health, University of Southampton, Southampton, UK.
Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK.

Htoo A Wai (HA)

Faculty of Medicine, Human Development and Health, University of Southampton, Southampton, UK.

Ian Davies (I)

Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

Hassan E Moledina (HE)

Faculty of Medicine, Human Development and Health, University of Southampton, Southampton, UK.

April Ruiz (A)

Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.

Tessy Thomas (T)

Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.

David Bunyan (D)

Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, UK.
Faculty of Medicine, University of Southampton, Southampton, UK.

N Simon Thomas (NS)

Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury, UK.
Faculty of Medicine, University of Southampton, Southampton, UK.

Christine P Burren (CP)

Department of Paediatric Endocrinology and Diabetes, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Bristol Medical School, Department of Translational Health Sciences, University of Bristol, Bristol, UK.

Lynn Greenhalgh (L)

Liverpool Centre for Genomic Medicine, Crown Street, Liverpool, UK.

Melissa Lees (M)

North East Thames Regional Genomics Service, Great Ormond Street Hospital, London, UK.

Amanda Pichini (A)

Department of Clinical Genetics, University Hospitals Bristol and Weston Foundation Trust, Bristol, UK.
Genomics England, Dawson Hall, Charterhouse Square, London, UK.

Sarah F Smithson (SF)

Department of Clinical Genetics, University Hospitals Bristol and Weston Foundation Trust, Bristol, UK.

Ana Lisa Taylor Tavares (AL)

Genomics England, Dawson Hall, Charterhouse Square, London, UK.
Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge, UK.

Peter O'Donovan (P)

Genomics England, Dawson Hall, Charterhouse Square, London, UK.

Andrew G L Douglas (AGL)

Faculty of Medicine, Human Development and Health, University of Southampton, Southampton, UK.
Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Nicola Whiffin (N)

Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

Diana Baralle (D)

Faculty of Medicine, Human Development and Health, University of Southampton, Southampton, UK.
Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.

Jenny Lord (J)

Faculty of Medicine, Human Development and Health, University of Southampton, Southampton, UK. jenny.lord@soton.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH